검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | protein analysis (protein analysis) The Scientific and Technological R…·Chronic Myeloproliferative Disorde… ORR 63% |
|---|---|
Overview Program | protein analysis |
Overview Company | The Scientific and Technological Research Council of Turkey |
Overview Modality | ANTIBODY |
Overview Target | Chronic Myeloproliferative Disorders |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | target within the Kras signalling pathway |
MoA Biomarker | Biomarkers in Patients With Rheumatoid Arthritis but Normal ESR/CRP Receiving Biological/Targeted Synthetic D |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Hematological Indices as Biomarkers in Patients With Rheumatoid Arthritis but Normal ESR/CRP Receiving Biological/Targeted Synthetic DMARDs.. Evidence indicates that hematological indices, such as neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and neutrophil-to-hemoglobin and lymphocyte (NHL), are valuable for assessing disease activity in rheumatoid arthritis (RA)… |
Clinical Primary efficacy | ORR 63% |
Clinical ORR | 63% |
Clinical Result source | ClinicalTrials.gov NCT00769379 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | protein analysis (protein analysis) The Scientific and Technological R…·Chronic Myeloproliferative Disorde… ORR 63% |
|---|---|
Overview Program | protein analysis |
Overview Company | The Scientific and Technological Research Council of Turkey |
Overview Modality | ANTIBODY |
Overview Target | Chronic Myeloproliferative Disorders |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | target within the Kras signalling pathway |
MoA Biomarker | Biomarkers in Patients With Rheumatoid Arthritis but Normal ESR/CRP Receiving Biological/Targeted Synthetic D |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Hematological Indices as Biomarkers in Patients With Rheumatoid Arthritis but Normal ESR/CRP Receiving Biological/Targeted Synthetic DMARDs.. Evidence indicates that hematological indices, such as neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and neutrophil-to-hemoglobin and lymphocyte (NHL), are valuable for assessing disease activity in rheumatoid arthritis (RA)… |
Clinical Primary efficacy | ORR 63% |
Clinical ORR | 63% |
Clinical Result source | ClinicalTrials.gov NCT00769379 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교